利好即砸盘有缅A之_老虎社区_美港股上老虎 - 老虎社区

利好即砸盘有缅A之风

Beam Therapeutics在欧洲呼吸学会2026年大会上公布Beam-302治疗α-1抗胰蛋白酶缺乏症1/2期临床试验最新数据

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":605779304116248,"tweetId":"605779304116248","gmtCreate":1788873679307,"gmtModify":1788873681408,"author":{"id":4091799483385130,"idStr":"4091799483385130","authorId":4091799483385130,"authorIdStr":"4091799483385130","name":"股市9527","avatar":"https://static.tigerbbs.com/7fd42aa6081828619228897cc07fe142","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":165,"starInvestorFlag":true,"fullDisclosureFlag":false,"starInvestorFollowerNum":164,"starInvestorOrderShareNum":44,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"showRor":false,"winRationPercentage":73.202614,"tradeVolumeEst":0},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>利好即砸盘 有缅A之风</p></body></html>","htmlText":"<html><head></head><body><p>利好即砸盘 有缅A之风</p></body></html>","text":"利好即砸盘 有缅A之风","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605779304116248","repostId":1133255075,"repostType":2,"repost":{"id":"1133255075","kind":"news","weMediaInfo":{"introduction":"全球快讯第一时间播报","home_visible":1,"media_name":"美股速递","id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"pubTimestamp":1788861674,"share":"https://www.laohunote.com/m/news/1133255075?lang=zh_CN&edition=full","pubTime":"2026-09-08 18:01","market":"us","language":"zh","title":"Beam Therapeutics在欧洲呼吸学会2026年大会上公布Beam-302治疗α-1抗胰蛋白酶缺乏症1/2期临床试验最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1133255075","media":"美股速递","summary":"Beam Therapeutics于欧洲呼吸学会2026年大会上，公布了Beam-302在α-1抗胰蛋白酶缺乏症治疗领域1/2期临床试验的最新临床数据。在大会现场，Beam Therapeutics的研发团队详细阐述了受试者的生物标志物变化、肺功能指标改善趋势以及药物耐受性情况。公司方面表示，这些更新数据进一步验证了Beam-302的潜在疾病修饰作用，并支持其后续临床开发路径的推进。业内分析人士指出，这一进展不仅关乎Beam药业自身管线价值的重估，也可能对AATD现有标准治疗格局构成远期挑战。","content":"<p>Beam Therapeutics于欧洲呼吸学会（ERS）2026年大会上，公布了Beam-302在α-1抗胰蛋白酶缺乏症（AATD）治疗领域1/2期临床试验的最新临床数据。此次披露涵盖疗效与安全性评估的阶段性成果，为这一罕见遗传病的靶向治疗探索注入了新的临床证据。值得关注的是，该候选药物采用碱基编辑技术，直击疾病根源的基因突变位点，有望为AATD患者带来一次性的根本性治疗选择。在大会现场，Beam Therapeutics的研发团队详细阐述了受试者的生物标志物变化、肺功能指标改善趋势以及药物耐受性情况。公司方面表示，这些更新数据进一步验证了Beam-302的潜在疾病修饰作用，并支持其后续临床开发路径的推进。业内分析人士指出，这一进展不仅关乎Beam药业自身管线价值的重估，也可能对AATD现有标准治疗格局构成远期挑战。随着数据成熟度的提升，市场对该项目的关注热度正持续升温。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics在欧洲呼吸学会2026年大会上公布Beam-302治疗α-1抗胰蛋白酶缺乏症1/2期临床试验最新数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics在欧洲呼吸学会2026年大会上公布Beam-302治疗α-1抗胰蛋白酶缺乏症1/2期临床试验最新数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-09-08 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beam Therapeutics于欧洲呼吸学会（ERS）2026年大会上，公布了Beam-302在α-1抗胰蛋白酶缺乏症（AATD）治疗领域1/2期临床试验的最新临床数据。此次披露涵盖疗效与安全性评估的阶段性成果，为这一罕见遗传病的靶向治疗探索注入了新的临床证据。值得关注的是，该候选药物采用碱基编辑技术，直击疾病根源的基因突变位点，有望为AATD患者带来一次性的根本性治疗选择。在大会现场，Beam Therapeutics的研发团队详细阐述了受试者的生物标志物变化、肺功能指标改善趋势以及药物耐受性情况。公司方面表示，这些更新数据进一步验证了Beam-302的潜在疾病修饰作用，并支持其后续临床开发路径的推进。业内分析人士指出，这一进展不仅关乎Beam药业自身管线价值的重估，也可能对AATD现有标准治疗格局构成远期挑战。随着数据成熟度的提升，市场对该项目的关注热度正持续升温。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BEAM":"Beam Therapeutics, Inc.","BK4588":"碎股","BK4139":"生物科技","BK4556":"基因编辑","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓","BK4611":"AI医疗"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133255075","content_text":"Beam Therapeutics于欧洲呼吸学会（ERS）2026年大会上，公布了Beam-302在α-1抗胰蛋白酶缺乏症（AATD）治疗领域1/2期临床试验的最新临床数据。此次披露涵盖疗效与安全性评估的阶段性成果，为这一罕见遗传病的靶向治疗探索注入了新的临床证据。值得关注的是，该候选药物采用碱基编辑技术，直击疾病根源的基因突变位点，有望为AATD患者带来一次性的根本性治疗选择。在大会现场，Beam Therapeutics的研发团队详细阐述了受试者的生物标志物变化、肺功能指标改善趋势以及药物耐受性情况。公司方面表示，这些更新数据进一步验证了Beam-302的潜在疾病修饰作用，并支持其后续临床开发路径的推进。业内分析人士指出，这一进展不仅关乎Beam药业自身管线价值的重估，也可能对AATD现有标准治疗格局构成远期挑战。随着数据成熟度的提升，市场对该项目的关注热度正持续升温。","news_type":1,"symbols_score_info":{"BEAM":1}},"isVote":1,"tweetType":1,"viewCount":557,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/605779304116248"}